Track topics on Twitter Track topics that are important to you
ATX-MS-1467 is a novel treatment that was developed with the aim of working with the immune system to treat the underlying cause of disease rather than just treating the symptoms or suppressing the ...
Treatment of inflammatory and autoimmune diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis and multiple sclerosis.
The anti-inflammatory effects of fingolimod did not slow disease progression in primary progressive multiple sclerosis. Therapeutic strategies for primary progressive multiple sclerosis might need dif...
HACKENSACK, NJ -- The Consortium of Multiple Sclerosis Centers (CMSC), in collaboration with The France Foundation (TFF) and Nurse Practitioner Alternatives (NPA), has produced a Rehabilitation Primer...
In The Lancet, Fred Lublin and colleagues1 report negative results of a randomised, double-blind trial (INFORMS) assessing the efficacy of fingolimod, an oral sphingosine 1-phosphate receptor (S1PR) m...
(Edmonton) Research from the University of Alberta's Faculty of Medicine & Dentistry is trailblazing a potential new pathway for the treatment of multiple sclerosis (MS). The research, published in th...
A crucial development has been made in the treatment of Multiple Sclerosis (MS). A research team has demonstrated in an animal model that, following treatment with a specially synthesized plant peptid...
Genentech’s phase III studies of ocrelizumab in people with relapsing multiple sclerosis (MS) and primary progressive multiple sclerosis (PPMS) show positive results
(Brigham and Women's Hospital) A team of investigators has launched a study of individuals at risk for multiple sclerosis (MS) to better understand the sequence of events that leads some people to dev...
An estimated 100,000 Canadians live with multiple sclerosis; there is currently no cure for the disease. Modern scientific understanding has considered multiple sclerosis (MS) to be a disease contr...
To date, there are no available factors to predict the outcome after multiple sclerosis relapse.
Mortality and comorbidities in patients with multiple sclerosis compared with a population without multiple sclerosis: An observational study using the US Department of Defense administrative claims database.
Data are limited for mortality and comorbidities in patients with multiple sclerosis (MS).
Cognitive deficits are common in multiple sclerosis. Most previous studies investigating the imaging substrate of cognitive deficits in multiple sclerosis included patients with relatively short disea...
Cognitive impairment occurs from the early phases of multiple sclerosis (MS), and more frequently affects secondary progressive (SP) subjects than relapsing-remitting (RR).
In search of the missing heritability in multiple sclerosis (MS), additional approaches adding to the genetic discoveries of large genome-wide association studies are warranted.